TORONTO, March 26, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the fourth quarter and for the year ended December 31, 2020 and provided a corporate update.
Financial Review
Revenue for the three months ended December 31, 2020 was $535,000 compared to $746,000 for the same three month period last year. Revenue for the year ended December 31, 2020 was $2,101,000 compared to $2,868,000 for the prior year, representing a decrease of $767,000, or 27%. The majority of the decrease is due to the timing of orders for product revenue and the non-recurring technology transfer revenue. This was mitigated by an increase in royalty revenue, and revenue from the exclusive distribution agreement with Baxter International Inc. (“Baxter”).
For the quarter ended December 31, 2020, the Company reported operating costs of $2,682,000 compared to $2,160,000 for the corresponding period in 2019. Operating costs for the year ended December 31, 2020 amounted to $11,199,000 compared to $7,728,000 in 2019. Approximately half of the increase relates to non-recurring fees payable to a financial advisory services firm incurred in the first quarter of 2020, relating to a legacy financial advisory agreement. In addition, the Company continues to ramp up activity for its clinical development and regulatory program; it incurred approximately $275,000 in professional fees in connection with a withdrawn prospectus offering in early March 2020, a general increase in transactional activity that require legal services, and quarterly reviews performed by the Company’s auditors.
The Company continues to maintain a low cost operating structure for its base business operations. The Company anticipates its operating costs to increase throughout 2021 as Spectral’s Tigris trial enrollment is expected to increase significantly, combined with incremental costs associated with Dialco’s upcoming usability trial for DIMI and the increase in field resources for the marketing and commercialization activities of its RRT devices.
Loss for the quarter ended December 31, 2020 was $2,147,000 ($0.009 per share) compared a loss of $1,414,000 ($0.006 per share) for the same quarter last year. For the year ended December 31, 2020, the Company reported a loss of $9,098,000 ($0.04 per share), compared to a loss of $4,860,000 ($0.02 per share), for the year ended December 31, 2019.
The Company concluded the 2020 year with cash of $5,807,000 compared to $1,435,000 cash on hand as of December 31, 2019.
The total number of common shares outstanding for the Company was 236,755,745 as at December 31, 2020.
Corporate Highlights During & Subsequent to Fourth Quarter and Fiscal Year Ended December 31, 2020
Tigris Trial and Regulatory Program
Tigris trial patient enrollment and new trial site onboarding continue to be negatively impacted by the COVID-19 pandemic, with most trial site ICUs diverting their research resources and focus to conducting trials and treating COVID-19 positive patients since March 2020. While some Tigris sites have remained open to enrollment throughout the pandemic, enrollment patient accrual has been low.
-
Patient Enrollment
15 patients have been randomized to-date. While current enrollment is below pre-pandemic expectations, the Company continues to be pleased by the early results from the Tigris trial. While the existing randomized patient sample size is limited, the mortality outcome data to date is inline with the Company’s Euphrates post-hoc experience.
-
Clinical Trial Sites
The Tigris trial currently has 11 sites initiated, with room to expand to 15 sites. At the Company’s December Virtual Investor Day, the Company expected that 15 sites would be initiated by the end of the first quarter, 2021. The Company’s efforts to finalize new site start-up procedures have been postponed due to the COVID-19 pandemic, resulting in projected initiation of all 15 sites by the end of the third quarter, 2021.
The Company’s clinical team is in regular communication with trial site principal investigators and clinical staff. Based on these discussions, the Company anticipates a return to normalized recruitment activity levels, with all 11 sites indicating active screening status by early June.
-
Timing
The Company continues to focus on finalizing the Tigris trial within the reasonably shortest timelines. Despite the hurdles presented by the COVID-19 pandemic, the Company continues to drive for completion of the trial and approval in H1 2022.
Dialco
-
DIMI Usability Trial
On February 23, 2021, Dialco was granted Investigational Device Exemption (“IDE”) authorization by the United States Food and Drug Administration (“FDA”) to conduct a usability trial to demonstrate the safety and efficacy of DIMI for performing hemodialysis in the home environment. The approved IDE usability trial is expected to enroll 35 patients and is designed to evaluate the safety and efficacy of DIMI in the home setting by analyzing delivered dialysis dose and potential adverse events occurring during six weeks of use at home compared to six weeks of use in the hospital setting on the same patients. Dialco anticipates finalizing its RFP process to select its contract research organization (“CRO”) partner to run the trial shortly, as well as identifying and evaluating clinical sites that will participate in the trial. The usability trial is the final regulatory step towards FDA clearance for in-home use of DIMI.
-
Infomed Agreement Update
Dialco is in late-stage renewal negotiations for the DIMI device, and anticipates finalizing a long-term licensing agreement in the coming days.
-
Health Canada DIMI Approval Update
Dialco had previously submitted an application to Health Canada in the second quarter of 2020 for in-home use approval for its DIMI device. The Company anticipates that Health Canada approval is imminent.
-
SAMI Commercialization
Throughout 2020, Dialco initiated clinical evaluations of SAMI at the University of Michigan in Ann Arbor and the Scarborough General Hospital (“SGH”) in Toronto. In the first quarter of 2021, SGH committed to the purchase of three SAMI units after a successful clinical evaluation of the SAMI device. Although the SGH purchase is limited in overall value, this transaction has qualified Dialco to become a Plexxus supplier of renal replacement devices. Plexxus is a leading health care supply chain organization, which delivers purchasing services to hospital networks throughout Ontario.
-
MDSAP Certification
On November 24, 2020, Dialco received its Medical Device Single Audit Program (“MDSAP”) certification for “the design, manufacture, installation and service of equipment for extracorporeal blood purification and its related disposal” under ISO 13485 for Canada and the United States. MDSAP is the highest quality and regulatory standard in the medical device industry, and validates both Spectral’s and Dialco’s commitment to maintaining the highest quality assurance standards within the medical device industry. Additionally, MDSAP certification is a Health Canada mandated requirement to sell medical devices in Canada, which is an important component to Dialco’s commercialization rollout plans.
Warrant Exercise
Subsequent to the year end, 2,114,999 warrants were exercised at a price of $0.45 per warrant. Accordingly, the Company received proceeds of $952,000. The Company issued share purchase warrants in connection with its financing that closed on April 23, 2018, which entitled each holder the right to purchase one common share of the Company at an exercise price of $0.45 per share for a three-year period ending April 20, 2021 (“April 2018 Warrants”). A total of 5,357,332, warrants (or $2,411,000) exercisable at a price of $0.45 remain outstanding. The Company anticipates all of the April 2018 Warrants will be exercised based on solicitation of the warrant holders.
Spectral Transition of Senior Leadership Team
In March 2021, the Company announced the appointment of Chris Seto as Chief Executive Officer (effective April 1, 2021), and the appointment of Dr. John Kellum as Chief Medical Officer. Mr. Seto brings over 25 years of capital markets and financial management experience and will focus the Company on achieving regulatory milestones and product commercialization. Dr. Kellum is considered one of the world’s foremost experts on blood purification and acute kidney injury (“AKI”), and he will be integral in driving the Tigris trial to a successful completion and help guide the commercial rollout of Dialco’s SAMI and DIMI platforms targeting both the acute and chronic renal dialysis therapy markets. Dr. Paul Walker will remain on the Board of Directors, and will support Dr. Kellum’s leadership of the Tigris trial.
U.S. Listing Update
The Company continues to prepare for a potential listing on a senior U.S. exchange. While management and the Board believe a senior U.S. listing aligns with the goals of the business and its stakeholders, timing is still to be determined.
About Spectral
Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.
Spectral, through its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”), is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market. Dialco is also seeking regulatory approval for “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use. “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.
Forward-looking statement
Information
in
this
news
release
that
is
not
current
or
historical
factual
information
may
constitute
forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management
as
well
as
information
currently
available
to
it.
While
these
assumptions
were
considered
reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are
subject
to
a
number
of
risks
and
uncertainties,
including
the
availability
of
funds
and
resources
to
pursue
R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
For further information, please contact:
David Waldman/Natalya Rudman
US Investor Relations
Crescendo Communications, LLC
212-671-1020
[email protected] |
|
|
Spectral Medical Inc.
Consolidated Statements of Financial Position
(in thousands of Canadian dollars)
| |
December 31
2020
|
|
|
December 31
2019
|
|
| |
$
|
|
|
$
|
|
| |
|
|
|
|
Assets
|
|
|
|
|
Current assets
|
|
|
|
| Cash |
5,807 |
|
|
1,435 |
|
| Trade and other receivables |
260 |
|
|
271 |
|
| Inventories |
348 |
|
|
276 |
|
| Prepayments and other assets |
389 |
|
|
155 |
|
| Contract assets |
– |
|
|
519 |
|
| |
6,804 |
|
|
2,656 |
|
|
Non-current assets
|
|
|
|
| Right-of-use-asset |
625 |
|
|
719 |
|
| Property and equipment |
488 |
|
|
368 |
|
| Intangible asset |
246 |
|
|
263 |
|
|
Total assets
|
8,163
|
|
|
4,006
|
|
| |
|
|
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
| Trade and other payables |
2,141 |
|
|
1,002 |
|
| Current portion of contract liabilities |
676 |
|
|
– |
|
| Current portion of lease liability |
85 |
|
|
77 |
|
| |
2,902 |
|
|
1,079 |
|
|
Non-current liability
|
|
|
|
| Lease liability |
582 |
|
|
667 |
|
| Non-current portion of contract liabilities |
5,348 |
|
|
– |
|
|
Total liabilities
|
8,832
|
|
|
1,746
|
|
| |
|
|
|
|
Shareholders’ (deficiency) equity
|
|
|
|
| Share capital |
71,870 |
|
|
66,837 |
|
| Contributed surplus |
7,981 |
|
|
7,981 |
|
| Share-based compensation |
6,771 |
|
|
6,183 |
|
| Warrants |
2,418 |
|
|
1,870 |
|
| Deficit |
(89,709 |
) |
|
(80,611 |
) |
|
Total shareholders’ (deficiency) equity
|
(669
|
)
|
|
2,260
|
|
| |
|
|
|
Total liabilities and shareholders’
(deficiency) equity
|
8,163
|
|
|
4,006
|
|
Spectral Medical Inc.
Consolidated Statements of Loss and Comprehensive Loss
For the years ended December 31, 2020 and 2019
(in thousands of Canadian dollars, except for share and per share data)
| |
2020
|
|
|
2019
|
|
| |
$
|
|
|
$
|
|
| |
|
|
|
|
Revenue
|
2,101
|
|
|
2,868
|
|
| |
|
|
|
|
Expenses
|
|
|
|
| Changes in inventories of finished goods and work-in-process |
127 |
|
|
291 |
|
| Raw materials and consumables used |
501 |
|
|
359 |
|
| Salaries and benefits |
4,750 |
|
|
3,826 |
|
| Consulting and professional fees |
4,064 |
|
|
1,499 |
|
| Regulatory and investor relations |
541 |
|
|
514 |
|
| Travel and entertainment |
146 |
|
|
326 |
|
| Facilities and communication |
361 |
|
|
300 |
|
| Insurance |
248 |
|
|
238 |
|
| Depreciation and amortization |
304 |
|
|
278 |
|
| Interest expense on lease liability |
32 |
|
|
36 |
|
| Foreign exchange (gain) loss |
(7 |
) |
|
114 |
|
| Other expense (income) |
148 |
|
|
(60 |
) |
| (Gain) loss on disposal of property and equipment |
(16 |
) |
|
7 |
|
| |
11,199 |
|
|
7,728 |
|
| |
|
|
|
|
Loss and comprehensive loss for the year
|
(9,098
|
)
|
|
(4,860
|
)
|
| |
|
|
|
|
Basic and diluted loss per common share
|
(0.04
|
)
|
|
(0.02
|
)
|
| |
|
|
|
Weighted average number of common shares
outstanding – basic and diluted
|
232,502,463
|
|
|
225,731,215
|
|
Spectral Medical Inc.
Consolidated Statements of Changes in Shareholders’ (Deficiency) Equity
For the years ended December 31, 2020 and 2019
(in thousands of Canadian dollars)
| |
Issued capital
|
Contributed
surplus
|
Share-based
compensation
|
Warrants
|
Deficit
|
|
Total
Shareholders’
(deficiency)
equity
|
|
| |
Number
|
$
|
$
|
$
|
$
|
$
|
|
$
|
|
|
Balance, January 1, 2019
|
225,591,183
|
66,646
|
7,981
|
5,564
|
|
1,930
|
|
(75,751
|
)
|
6,370
|
|
| Share options exercised |
10,500 |
7 |
– |
(3 |
) |
– |
|
– |
|
4 |
|
| Warrants exercised |
275,000 |
184 |
– |
– |
|
(60 |
) |
– |
|
124 |
|
| Loss and comprehensive loss for the year |
– |
– |
– |
– |
|
– |
|
(4,860 |
) |
(4,860 |
) |
| Share-based compensation |
– |
– |
– |
622 |
|
– |
|
– |
|
622 |
|
|
Balance, December 31, 2019
|
225,876,683
|
66,837
|
7,981
|
6,183
|
|
1,870
|
|
(80,611
|
)
|
2,260
|
|
| Public offering |
8,500,000 |
3,526 |
– |
– |
|
788 |
|
– |
|
4,314 |
|
| Share options exercised |
1,279,062 |
772 |
– |
(292 |
) |
– |
|
– |
|
480 |
|
| Warrants exercised |
1,100,000 |
735 |
– |
– |
|
(240 |
) |
– |
|
495 |
|
| Loss and comprehensive loss for the year |
– |
– |
– |
– |
|
– |
|
(9,098 |
) |
(9,098 |
) |
| Share-based compensation |
– |
– |
– |
880 |
|
– |
|
– |
|
880 |
|
|
Balance, December 31, 2020
|
236,755,745
|
71,870
|
7,981
|
6,771
|
|
2,418
|
|
(89,709
|
)
|
(669
|
)
|
Spectral Medical Inc.
Consolidated Statements of Cash Flows
For the years ended December 31, 2020 and 2019
(in thousands of Canadian dollars)
| |
2020
|
|
|
2019
|
|
| |
$
|
|
|
$
|
|
|
Cash flow provided by (used in)
|
|
|
|
| |
|
|
|
|
Operating activities
|
|
|
|
| Loss and comprehensive loss for the year |
(9,098 |
) |
|
(4,860 |
) |
| Adjustments for: |
|
|
|
| Depreciation on right-of-use asset |
94 |
|
|
94 |
|
| Depreciation on property and equipment |
193 |
|
|
163 |
|
| Amortization of intangible asset |
17 |
|
|
21 |
|
| Interest expense on lease liability |
32 |
|
|
36 |
|
| Unrealized foreign exchange loss on cash |
187 |
|
|
57 |
|
| Share-based compensation |
880 |
|
|
622 |
|
| (Gain) loss on disposal of property and equipment |
(16 |
) |
|
7 |
|
| Changes in items of working capital: |
|
|
|
| Trade and other receivables |
11 |
|
|
1,162 |
|
| Inventories |
(72 |
) |
|
(79 |
) |
| Prepayments and other assets |
(234 |
) |
|
37 |
|
| Contract asset |
519 |
|
|
(393 |
) |
| Trade and other payables |
1,139 |
|
|
502 |
|
| Contract liabilities |
6,024 |
|
|
(107 |
) |
|
Net cash used in operating activities
|
(324 |
) |
|
(2,738 |
) |
| |
|
|
|
|
Investing activities
|
|
|
|
| Proceeds on disposal of property and equipment |
18 |
|
|
– |
|
| Property and equipment expenditures |
(315 |
) |
|
(161 |
) |
|
Net cash used in investing activities
|
(297 |
) |
|
(161 |
) |
| |
|
|
|
|
Financing activities
|
|
|
|
| Proceeds from public offering |
5,100 |
|
|
– |
|
| Transaction costs paid |
(786 |
) |
|
– |
|
| Lease liability payments |
(109 |
) |
|
(105 |
) |
| Share options exercised |
480 |
|
|
4 |
|
| Warrants exercised |
495 |
|
|
124 |
|
|
Net cash provided by financing activities
|
5,180 |
|
|
23 |
|
| |
|
|
|
| Increase (decrease) in cash |
4,559 |
|
|
(2,876 |
) |
| Effects of exchange rate changes on cash |
(187 |
) |
|
(57 |
) |
| Cash, beginning of year |
1,435 |
|
|
4,368 |
|
|
Cash, end of year
|
5,807
|
|
|
1,435
|
|
